ID: ALA400542

Max Phase: Preclinical

Molecular Formula: C18H18Cl2N6O

Molecular Weight: 405.29

Molecule Type: Small molecule

Representations

Canonical SMILES:  N#Cc1nc(NCc2ccc(Cl)c(Cl)c2)c2ncn(CCCCCO)c2n1

Standard InChI:  InChI=1S/C18H18Cl2N6O/c19-13-5-4-12(8-14(13)20)10-22-17-16-18(25-15(9-21)24-17)26(11-23-16)6-2-1-3-7-27/h4-5,8,11,27H,1-3,6-7,10H2,(H,22,24,25)

Standard InChI Key:  XGGNEKDNMIBGDR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 405.29

Molecular Weight (Monoisotopic): 404.0919

AlogP: 3.78

#Rotatable Bonds: 8

Polar Surface Area: 99.65

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 1.15

CX LogP: 3.79

CX LogD: 3.79

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.55

Np Likeness Score: -1.18

References

1. Mallari JP, Shelat AA, Obrien T, Caffrey CR, Kosinski A, Connelly M, Harbut M, Greenbaum D, McKerrow JH, Guy RK..  (2008)  Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB.,  51  (3): [PMID:18173229] [10.1021/jm070760l]

2. Mallari JP, Zhu F, Lemoff A, Kaiser M, Lu M, Brun R, Guy RK..  (2010)  Optimization of purine-nitrile TbcatB inhibitors for use in vivo and evaluation of efficacy in murine models.,  18  (23): [PMID:21051236] [10.1016/j.bmc.2010.09.073]

Source

Source(1):

• Scientific Literature